Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nauheim – page 13

1 333 clinical trials in Bad Nauheim, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nauheim at a glance
1 333
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 333 trials in Bad Nauheim

Open in trial search

Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB

Study of MK-1084 plus durvalumab versus placebo plus durvalumab in patients with locally advanced KRAS G12C‑mutant non‑small cell lung cancer after chemoradiotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Merck Sharp & Dohme LLC

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efanesoctocog Alfa
  • Sponsor:GWT-Tud GmbH

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Randomized Study of Intravitreal mk-8748 Compared with Aflibercept in Patients with Neovascular Age‑Related Macular Degeneration

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DNL952 in Adults with Late‑Onset Pompe Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:DNL952
  • Sponsor:Denali Therapeutics Inc.

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nauheim

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on hypertrophic cardiomyopathy treatments, including trials of mavacamten and aficamten. Research also covers advanced therapies for heart failure and pulmonary hypertension management.

  • Cardiac Structure Improvement
  • Heart Function Enhancement
  • Pulmonary Hypertension Treatment

Long-term safety and efficacy evaluations of novel cardiovascular medications are prioritized.

02 Oncology Studies

Advanced research in breast cancer treatment, particularly focusing on HER2-negative and triple-negative variants. Studies evaluate innovative combination therapies including atezolizumab and targeted treatments.

  • Neoadjuvant Therapies
  • Immunotherapy Applications
  • Treatment Resistance

Emphasis on improving survival rates and reducing recurrence in early-stage breast cancer.

03 Inflammatory Conditions

Clinical investigations of inflammatory diseases including myositis and arteritis. Studies evaluate new biological treatments and their long-term effectiveness in managing chronic inflammatory conditions.

  • Autoimmune Disorders
  • Novel Biologics
  • Disease Modification

Focus on developing targeted therapies for better disease control and improved patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.